Commentary: Baseline systemic immune-inflammation index and a novel FLIPI-SII model predict POD24 and long-term survival in grade 1–3a follicular lymphoma - Summary - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Analysis: The Baseline Systemic Immune-Inflammation Index and the Innovative FLIPI-SII Model as Predictors of POD24 and Long-Term Outcomes in Grade 1–3a Follicular Lymphoma
To evaluate the prognostic value of the baseline systemic immune-inflammation index (SII) and the FLIPI-SII model in predicting progression of disease within 24 months (POD24) and long-term outcomes in patients with grade 1–3a follicular lymphoma.
Approach:
Prognostic Model Development: Yu et al. constructed a six-item FLIPI-SII model by integrating SII with the established Follicular Lymphoma International Prognostic Index (FLIPI).
Validation: The model underwent both internal and multicenter external validation to assess its prognostic capabilities.
Key Findings:
Elevated baseline SII is independently associated with poorer overall survival (OS) and progression-free survival (PFS).
FLIPI-SII serves primarily as a prognostic stratification tool rather than a treatment-selection model.
The study highlights the distinction between prognostic information and treatment-effect prediction.
Interpretation:
FLIPI-SII is relevant for risk stratification but does not currently inform treatment selection.
Limitations:
The study lacked a sufficiently balanced comparator group to assess differential treatment benefit based on SII status.
The method of evaluating POD24 may introduce sensitivity issues regarding progression status assessment.
Conclusion:
FLIPI-SII is a promising tool for prognostic stratification in follicular lymphoma.
New research co-led by a Roswell Park Comprehensive Cancer Center leukemia expert highlights a promising investigational treatment approach using the targeted therapy ziftomenib for patients with a difficult-to-treat form of acute myeloid leukemia (AML).
